Hypoxia Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Hypoxia Treatment Market is segmented By Type (Hypoxic Hypoxia, Hypemic Hypoxic, Histotoxic Hypoxia, Stagnant Hypoxia), By Disease Type (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pneumonia, Others), By End Users (Hospitals, Specialty Clinics, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Hypoxia Treatment Market Size

Global Hypoxia Treatment Market reached US$ 77.6 million in 2022 and is expected to reach US$ 134.3 million by 2030 growing with a CAGR of 7.2% during the forecast period 2024-2031.

Hypoxia is the main cause of many diseases which include covid-19, asthma, chronic obstructive pulmonary diseases, and pneumonia. Hypoxemia condition depicts low oxygen levels in the body tissues. Shortness of breath, fatigue, headache, and dizziness are the common symptoms faced by the patients. The treatment of hypoxia includes oxygen therapy where the oxygen is delivered through a mask or tubes. In a few cases, mechanical ventilation is performed to supply oxygen and to improve breathing.

The health worker administering oxygen is responsible for monitoring the patient’s response and checking the oxygen saturation levels within the target range. As the market evolves, the increasing prevalence of hypoxia conditions, increasing clinical trials, continuous advancements in technology, increasing consumer demand, and growing FDA approvals are likely to boost the hypoxia treatment market.

Hypoxia Treatment Market Scope

For more details on this report –Request for Sample

Hypoxia Treatment Market Dynamics

Rising FDA Approvals for Hypoxia Conditions are Expected to Drive Global Hypoxia Treatment Market

The increasing FDA approvals for hypoxia conditions such as asthma, COPD, and pneumonia are major drivers for market growth. Also, many key players play a major role in the advancements of the market by launching new products and services. Conditions that can lead to hypoxia include anemia, asthma bronchitis, chronic obstructive pulmonary disease (COPD), congenital heart defects, congestive heart failure, emphysema, pneumonia (bacterial and viral) etc.

For instance, on March 15, 2022, the U.S. Food and Drug Administration (FDA) approved the first generic of Symbicort Inhalation Aerosol for the treatment of two common pulmonary health conditions that is asthma in patients six years of age and older and the maintenance treatment of airflow obstruction and reducing exacerbations for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis.

On May 23, 2023, the U.S. Food and Drug Administration approved Xacduro which is a new treatment for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii-calcoaceticus complex for patients 18 years of age and older. Xacduro consists of sulbactam, a drug structurally related to penicillin, and durlobactam.

Increasing Clinical Trials for Hypoxia Conditions are Expected to Drive the Global Hypoxia Treatment Market

According to ClinicalTrials.gov, on April 25, 2023, Capital Medical University conducted a clinical trial on an exploratory study of intermittent hypoxia treatment in chronic cerebral hypoperfusion. This interventional study aims to investigate the safety and efficacy of intermittent hypoxia treatment in patients with chronic cerebral hypoperfusion. This study is an exploratory study combining intermittent hypoxia treatment with chronic cerebral hypoperfusion, aiming to preliminarily explore the safety and potential effectiveness of intermittent hypoxia treatment in the use of chronic cerebral hypoperfusion.

Additionally, on Jan 18, 2023, Shanghai East Hospital conducted an interventional study on UC-MSCs in the treatment of severe and critical COVID-19 patients with refractory hypoxia. The main aim of the study is to test the efficacy and safety of umbilical cord mesenchymal stem cells (UC- MSCs) in the treatment of severe and critical COVID-19 patients with refractory hypoxia even after sufficient standard treatment according to the tenth edition of Chinese guidelines for COVID-19 infection. Hence, owing to the above factors, the market is expected to drive over the forecast period.

Lack of Awareness Associated with Hypoxia Conditions such as COPD is Expected to Hamper Global Hypoxia Treatment Market Growth

According to Dove Press, epidemiological studies were conducted to access the prevalence of COPD  in the Aseer region of Saudi Arabia. The awareness regarding the COPD condition was low among the people of the region. Only 34.0% correctly knew that quitting smoking has an important role in preventing COPD. This study needs an urgent need of improving awareness of COPD and its risk factors in the general population. This subject should be strengthened in the curriculum and discussed in public campaigns and seminars. Furthermore, nationwide study is required to help the policymakers for implementing suitable preventive and curative strategies to promote the pulmonary health of the population.

Hypoxia Treatment Market Segment Analysis

The global hypoxia treatment market is segmented based on type, disease type, end users, and region.

Owing to the Increasing Prevalence of Hypoxia Conditions, Rising Clinical Trials, the Asthma Segment Accounted for Approximately 32.5% of the Hypoxia Treatment  Market Share

Hypoxia is a condition where the availability of oxygen is low in the body tissues. This condition is mainly caused by low oxygen tension in the arterial blood due to the inability of the lungs to sufficiently oxygenate the blood. Asthma is one of the most common hypoxia conditions faced by people. It is a condition where the airways become narrower and produces more mucus. This condition may cause difficulty in breathing, chest pains, coughing, etc

For instance, on Jan 11 2023, Airsupra for the treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older has received the FDA approval. The approval was based on results from the MANDALA and DENALI Phase III trials.1,2 In MANDALA, Airsupra significantly reduced the risk of severe exacerbations compared to albuterol in patients with moderate to severe asthma when used as an as-needed rescue medication in response to symptoms. Thus, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.

Source: DataM Intelligence Analysis (2023)

Top of Form

Hypoxia Treatment Market Geographical Share

North America Accounted for Approximately 38.4% of the Market Share in 2022, Owing to the Increasing Research and Development Activities and Well-Established Healthcare Infrastructure 

The North American region is anticipated to experience growth in the field of hypoxia treatments due to factors such as rising research and development efforts, a robust healthcare infrastructure, and supportive reimbursement systems. These factors contribute to increased accessibility for patients to access advanced therapies, facilitating the adoption of cutting-edge treatments. This trend is expected to drive the North American region's progress in hypoxia treatment throughout the forecast period.

For instance, on Aug 13, 2021, Merck & Co. announced that WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor received FDA approval for the treatment of adult patients with Von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors.

WELIREG is the first HIF-2α inhibitor therapy approved in the U.S. As an inhibitor of HIF-2α, WELIREG reduces transcription and expression of HIF-2α target genes associated with cellular proliferation, angiogenesis, and tumor growth.

Source: DataM Intelligence Analysis (2023)

Hypoxia Treatment Market Companies

The major global players in the market include CASI Pharmaceuticals Inc., Aileron Therapeutics, Inc., Lupin Pharmaceuticals, Inc., PharmaShots, Hancock Medical Inc., Hamilton Company, Spotlight Labs, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., and Merck & Co among others.

COVID-19 Impact Analysis

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict has had significant implications for various aspects of life in both countries, including healthcare and the management of hypoxic diseases such as asthma and COPD. The conflict has led to the destruction and disruption of healthcare infrastructure in affected regions. Medical facilities, including hospitals and Specialty Clinics, are damaged or inaccessible, making it challenging for patients with hypoxic diseases to receive proper diagnosis, treatment, and follow-up care.

The conflict resulted in limited availability of medical resources, including medical devices, medications, and specialized healthcare professionals. This scarcity led to delays in diagnosis, inadequate treatment options, and suboptimal disease management for hypoxic disorders patients.

By Type

• Hypoxic Hypoxia
• Hypemic Hypoxia
• Histotoxic Hypoxia
• Stagnant Hypoxia

By Disease Type

• Asthma
• Chronic Obstructive Pulmonary disease (COPD)
• Pneumonia
• Others

By End Users

• Hospitals
• Specialty Clinics
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• On Feb 1, 2023, GSK announced that Jesduvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) has received the US Food and Drug Administration (FDA), for the once-a-day treatment of anaemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for four months. Jesduvroq is the first innovative medicine for anemia treatment in over 30 years and the only HIF-PHI approved in the US, providing a new oral and convenient option for patients in the US with anemia of CKD on dialysis.
• On June 20, 2023, Akebia Therapeutics, Inc. announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization for Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis. The Swissmedic approval of Vafseo is based on data from a development program that included over 7,500 patients, including the global Phase 3 clinical program of vadadustat for the treatment of anemia due to CKD in adult patients on dialysis.

Why Purchase the Report?

• To visualize the global hypoxia treatment market segmentation based on the type, disease type, end users, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of hypoxia treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global hypoxia treatment market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies